

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Appl. No. : 10/648536 Confirmation No. 4649
Applicant : LOCKERBIE, Robert Owen, et al.
Filed : 08/25/2003
Title: Induction of and Maintenance of Nucleic Acid Damage in Pathogens
Using Riboflavin and Light
TC/A.U. : 1656
Examiner : LEE, Jae W.
Docket No. : PB0175-US02
Customer No.: 24994

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Submission of Terminal Disclaimer

Sirs,

In response to the Examiner's email instruction to Applicants' representative on January 14, 2011, please enter the following for the above-identified application.

Remarks begin on page 2 of this paper.

Terminal Disclaimer begins on page 3 of this paper.

Remarks

Applicants appreciate the email instruction from the Examiner. Please charge deposit account 03-2316 for the required \$140.00 fee for terminal disclaimer over US Patent 7,648,699.


Applicants wish to bring the Examiner's attention to the following facts. Assignee Navigant Biotechnologies, LLC, now known as CaridianBCT Biotechnologies, LLC, voluntarily filed a terminal disclaimer over US Patent 6,258,577 with a \$130.00 fee payment on August 6, 2007. The terminal disclaimer was to overcome the double patenting rejection in the 1st Office Action dated February 6, 2007. Per the Examiner's telephone conference with Applicants' representative on January 12, 2011, Assignee filed again a terminal disclaimer over US Patent 6,258,577 with a \$140.00 fee. Since Assignee twice filed and paid for terminal disclaimers for the same patent, Applicants respectfully request the Commissioner to credit \$130.00 to deposit account number 03-2316.

If there are any questions, or if prosecution can be expedited in any manner by another telephone conference, the Examiner is urged to call Applicants representative at the below telephone number.

Respectfully submitted,

01-17-2011

Date



Laura Butterfield Arciniegas (47,466)
Attorney of Record
Telephone: (303) 231-4270